Timothy J. Carrothers

Author

Allergan (United States)

Also Known As

SaeHeum Song, T J Carrothers, T. J. Carrothers, Timothy Carrothers, Timothy J Carrothers, Timothy J. Carrothers

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Allergan (United States)AbbVie (United States)Pfizer (United States)Daiichi Sankyo (United States)AstraZeneca (United Kingdom)

About

Timothy J. Carrothers is an author at Allergan (United States) specializing in medicine, pharmacokinetics, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	99
2	Business	1	1	12
3	Engineering	1	1	244
4	Health Sciences	1	1	19
5	Public Health	1	1	12

Timothy J. Carrothers

Publications

801

Citations

H-Index

Page 1

	Year	Citations
Full-Scale Evaluation of <i>In Situ</i> Cometabolic Degradation of Trichloroethylene in Groundwater through Toluene Injection Perry L. McCarty, Mark N. Goltz, Gary D. Hopkins, Environmental Science & Technology Groundwater QualityEngineeringPeriodic Toluene InjectionChemical EngineeringEnvironmental Chemistry	1998	244
Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups Jianguo Li, Mark Lovern, Michelle Green, Clinical and Translational Science	2018	99
Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs Shashank Rohatagi, Timothy J. Carrothers, Jon Kuwabara‐Wagg, The Journal of Clinical Pharmacology Therapeutic Drug MonitoringHeart FailurePharmacokinetic ModelingQtc ProlongationPreclinical Drug Evaluation	2009	45
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis Timothy J. Carrothers, Jason Chittenden, Ian A. Critchley Clinical Pharmacology in Drug Development	2019	42
Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Manish Gupta, Bei Wang, Timothy J. Carrothers, Clinical Pharmacology in Drug Development	2013	39
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community‐Acquired Bacterial Pneumonia Todd Riccobene, Tatiana Khariton, William Knebel, The Journal of Clinical Pharmacology	2016	33
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older Richard C. Franzese, Lynn McFadyen, Kenny J. Watson, Clinical Pharmacology & Therapeutics	2021	28
Population Pharmacokinetics of Cariprazine and its Major Metabolites Antonia Periclou, Luann Phillips, Parviz Ghahramani, European Journal of Drug Metabolism and Pharmacokinetics	2020	26
<p>Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation</p> Christoph U. Correll, Rakesh K. Jain, Jonathan M. Meyer, Neuropsychiatric Disease and Treatment	2019	25
Model‐Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs Shashank Rohatagi, Timothy J. Carrothers, JinYan Jin, The Journal of Clinical Pharmacology Model-based ApproachPharmacotherapySystem PharmacologyPhysiologically-based Pharmacokinetic ModelingPparγ Agonist	2008	23

Page 1